echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > PNAs: computer technology helps to reveal the molecular mechanism of cancer deterioration

    PNAs: computer technology helps to reveal the molecular mechanism of cancer deterioration

    • Last Update: 2020-02-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    February 19, 2020 / BIOON / -- recently, a study led by children's Hospital of Philadelphia (CHOP) revealed the relationship between variable protein cleavage and oncogene The results were published in PNAS "Our research provides insights into the relationship between cancer driven genes and alternative splicing, and these findings can be used to guide the development of cancer therapies targeting alternative splicing," said Dr Xing, director of the center for computing and genomics Selective splicing is an essential molecular process in cells, which allows genes to encode different protein products according to the different positions of RNA cutting or splicing before transforming RNA into protein Cancer cells often use this process to produce proteins that promote growth and survival, allowing them to replicate and metastasize uncontrolled This happens in many cancers, including prostate cancer However, scientists do not fully understand the process leading to this change (image source: www Pixabay Com) to better understand the causes and consequences of variable splicing changes in cancer progression, the team studied RNA sequences in nearly 900 prostate tissue samples, including healthy prostate tissue and local or aggressive metastatic tumor tissue To effectively analyze such a large data set, the team created a new calculator called rmats turbo Using the procedure, the researchers identified more than 13000 variable splicing events in the 900 prostate samples Next, the team developed an analytical tool called pegasas (alternative splicing pathway enrichment guide activity study) to identify potential cancer driving genes and pathways associated with these alternative splicing changes They found that Myc, a gene involved in normal cell function, has been amplified in many cancers and is associated with alternative splicing changes in genes that regulate alternative splicing Using engineered human prostate cells to turn on or off myc activity, the researchers further confirmed that these alternative splicing changes were indeed driven by Myc The researchers then applied the same pegasas strategy to breast and lung cancer samples and found the same association between myc activity and other splices, suggesting that myc activation (which leads to splicing disruption) occurs in many cancers Source of information: new computational tools identify alternative splicing changes in aggressive cancers original source: John W Phillips El Al., "pathway guided analysis identifiers myc dependent alternative pre mRNA splicing in aggressive progress cancers," PNAs (2020) Www.pnas.org/cgi/doi/10.1073/pnas.1915975117
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.